Form 4: PTC Therapeutics Executive Lee Scott Golden Acquires Shares and Options
SEC Form 4
Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, reports acquisition of shares and stock options.
Summary
- Lee Scott Golden, an executive at PTC Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On January 3, 2025, Golden acquired 20,000 shares of common stock and was granted options to purchase 50,000 shares.
- The restricted stock units vest in four equal installments starting January 3, 2026.
- The stock options also vest over four years, beginning January 3, 2026.
- Golden also owns 80,659 shares of common stock, including shares acquired through the employee stock purchase plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing related to executive compensation. The acquisition of shares and options suggests confidence, but it's not overwhelmingly positive.
Positives
- The acquisition of shares and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain explicit forward-looking statements, but the vesting schedules for the stock and options suggest a multi-year commitment from the executive.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. These filings are common across publicly traded companies in the biotechnology and pharmaceutical sectors.
Comparison to Industry Standards
- Stock option grants and restricted stock units are standard components of executive compensation packages in the biotechnology industry.
- Vesting schedules of four years are typical to incentivize long-term performance.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- Shareholders may view the executive's increased stake in the company positively, as it aligns management's interests with theirs.
- Employees may see this as a sign of stability and confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| June 30, 2024 | End of period for employee stock purchase plan, resulting in acquisition of 445 shares. |
| December 31, 2024 | End of period for employee stock purchase plan, resulting in acquisition of 401 shares. |
| January 3, 2025 | Date of transaction: Acquisition of 20,000 shares and grant of options for 50,000 shares. |
| January 3, 2026 | First vesting date for both restricted stock units and stock options. |
| April 3, 2026 | First three-month vesting date for stock options after the initial vesting date. |
| January 2, 2035 | Expiration date for the stock options. |
| January 7, 2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.